El negocio bursátil de PUMA BIOTECHNOLOGY – Observatorio de biopolitica
Resumen: Puma Biotechnology y Pierre Fabre modifican el acuerdo de licencia de NERLYNX® para incluir la Gran China | Business Wire
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
Puma Biotechnology
PUMA BIOTECHNOLOGY, INC. FORM 8-K/A - Shareholder.com
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire